Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Mercator Medsystems Inc. is active in the Medical Devices & Mechanical Engineering technology area with 4 pending office actions. These actions are distributed across 4 distinct examiners, showing a lack of examiner overlap in the current portfolio. Despite the number of examiners, the work is contained within 2 distinct art units. RAHMANI, NILOOFAR is the busiest examiner, though they only account for 1 pending office action.
This distribution suggests that the 4 pending office actions are spread evenly among the 4 distinct examiners. The use of 2 distinct art units indicates that while the technology is within a single broad area, it touches on different sub-specialties. For a practitioner, this means preparing for different examination styles across the 4 pending office actions. The diversity of examiners relative to the 4 pending actions suggests that no single examiner's tendencies will dominate the portfolio's overall success. Because RAHMANI, NILOOFAR has 1 pending office action, the workload is balanced across the 4 distinct examiners and 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| GRAY, PHILLIP A | 1 | 74.1% | +10.8% |
| BOSWORTH, KAMI A | 1 | 69.1% | +28.6% |
| KOO, BENJAMIN K | 1 | 57.3% | +49.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 91d overdue |
| 18667884 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | RAHMANI, NILOOFAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 91d overdue |
| 18626751 | TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE | GRAY, PHILLIP A | — |
| 17491036 | PERIVASCULAR ANTI-INFLAMMATORY THERAPY FOR VENOUS THROMBOSIS | KOO, BENJAMIN K | — |
| Art Unit | Apps |
|---|---|
| 3783 | 3 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667884 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS | RAHMANI, NILOOFAR | 1691 | §101§102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18626751 | TREATMENT OF HYPERTENSION BY RENAL VASCULAR DELIVERY OF GUANETHIDINE | GRAY, PHILLIP A | 3783 | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18297328 | MEDICAL INSTRUMENT AND MEDICAL METHOD FOR LOCALIZED DRUG DELIVERY | BOSWORTH, KAMI A | 3783 | §103§112 | Final Rejection | 91d overdue | Pending | Apr 07, 2023 |
| 17491036 | PERIVASCULAR ANTI-INFLAMMATORY THERAPY FOR VENOUS THROMBOSIS | KOO, BENJAMIN K | 3783 | §103 | Non-Final OA | — | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMercator Medsystems Inc. has 4 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
Niloofar Rahmani has the most, with 1 of Mercator Medsystems Inc.'s pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
